| 3 min read
Pediatric brain cancer is extremely challenging to treat. Results from a Phase 1 cell therapy trial revealed encouraging long-term survival rates.
| 4 min read
Data on a new oral pill for Duchenne muscular dystrophy, a miss for a heart drug, a $10B acquisition of Crinetics, and more led the news this week.
| 3 min read
Researchers showed that an oral medication can activate worn-out T cells.
| 4 min read
7-methylxanthine is being reformulated into a sustained-release oral therapy aimed at improving long-term control of axial elongation in childhood myopia.
| 5 min read
The Synthetic Molecule Process Innovation Phorum brings together major pharma companies, regulators, and CDMOs to build consensus on pressing challenges in small molecule manufacturing. News
| 2 min read
For the first time, researchers imaged a human protein essential to the RNA interference process and found ways to design better siRNA drugs.
| 3 min read
Patient advocates warn that political momentum to reduce animal testing is outpacing the scientific validation of alternative methods.
| 5 min read
Therapeutic cancer vaccines are being reengineered to deliver stronger immune activation and longer-lasting protection against disease recurrence.
| 5 min read
New population-level data reveal unprecedented declines in cervical cancer among vaccinated cohorts, even as vaccination rates begin to slip in some countries.
| 5 min read
The approach identifies entirely new chemical structures that could help replenish a thinning antibiotic pipeline as resistance continues to rise.
| 4 min read
Phase 3 trial results for neurological drugs, an AI platform for central nervous system drug discovery, a novel long-acting flu antiviral, and more led the news this week.
Cancer Research News
Researchers are uncovering new ways to attack some of cancer’s most elusive drivers.
By stabilizing G-quadruplex DNA, a revived anticancer drug offers a new way to shut down a key oncogene.
Editor's Pick
Born to differentiate and heal, mesenchymal stem cells carry great potential for treating a wide spectrum of diseases.
In a journey fraught with heartache and persistence, medical research giants paved the way for successful bone marrow transplantation.
Multimedia
Philip Wills, Chief Commercial Officer of the Cell & Gene Therapy Division at Catalent, reflects on how the gene therapy industry is evolving from early scientific breakthroughs to commercial maturity.
Learn the key characteristics that determine whether an immunoassay generates accurate and reproducible data.
